Kornimate/medical-research-clean huggingface dataset:
ejaculatory and orgasmic dysfunction registry

Conditions: Ejaculatory Dysfunction; Premature Ejaculation; Delayed Ejaculation; Anorgasmia; Anejaculation; Dysejaculation; Dysorgasmia

Summary: the goal of this observational study is to evaluate the safety and efficacy of various therapies used to treat ejaculatory and/or orgasmic dysfunctions in men. the objective is to create a large, national registry designed to capture key outcomes for men being treated for ejaculatory and/or orgasmic dysfunction. participants will submit questionnaires about their diagnosis and treatment efficacy and multiple time intervals.

the objective of the current study is to create a large, national registry designed to capture key outcomes for men being treated for ejaculatory and/or orgasmic dysfunction. to accomplish this registry, cure pd has partnered with the sexual medicine society of north america (smsna) to help inform sexual medicine providers of the existence of the study and to help encourage patients to enroll. subjects meeting criteria will be offered study entry by their local provider who will refer them to an email address to indicate their interest. participants will then be administered questionnaires at baseline and every 3 months x 1 year, followed by every 6 months x 2 years. patient partners will also be allowed to enroll and will receive questionnaires on the same schedule (baseline, q3 months x 1 year, q6 months x 2 years).

Eligibility criteria:
inclusion criteria: * men being treated for either ejaculatory and/or orgasmic dysfunction * for partners, inclusion is being a sexual partner of a man with ejaculatory and/or orgasmic dysfunction who is receiving treatment exclusion criteria: * none

Keywords: ejaculatory dysfunction premature ejaculation delayed ejaculation anorgasmia anejaculation dysejaculation dysorgasmia
phase 1: randomized evaluation of a system to deliver mobile cognitive behavioral therapy

Conditions: Pain, Postoperative; Analgesics, Opioid

Summary: the clinical study described in this clinical investigation plan (cip) will be completed in two stages, phase i and phase ii. the results of phase i will confirm patient use of incaveo's eoa system with integrated mobile cbt but without tapering to improve the pain catastrophizing scale (pcs) scores, and secondarily scores on the vns pain scale, the tampa scale of kinesiophobia (tsk), and patient satisfaction scores in the subacute period (defined as 2 weeks to 3 months post tkr). statistically significant positive results on the pain catastrophizing scale (pcs) will trigger phase 2. phase 1 will also inform the detailed conditions and patient management algorithms for phase ii.

the incaveo end opioid addiction (eoa) system is an integrated pain management therapeutic and opioid tapering system providing alternate treatment options via self-service cognitive behavior therapy (cbt) built into a mobile software app, patient medication usage, and tracking of patient pros. it is designed to be used alongside usual standard of care using pill bottles or to simplify, usual care with pill bottles (ucpb) treatment practices. the incaveo eoa system is designed to improve a set of patient outcome measures, primarily pain catastrophizing scale (pcs) and secondarily the visual numeric pain (vns), kinesiophobia (tsk) and satisfaction scores while facilitating the ability of patients to taper off their pain medication faster than through the use of uspb in the management of post-operative pain. in order to reduce confounding variables, the study will focus on pain management following a single surgical procedure: total knee replacement (tkr) surgery.

Eligibility criteria:
inclusion criteria: 1. patient has a pain catastrophizing score \>16 2. 55 years of age and older. 3. english speaking. 4. has a smartphone (iphone). 5. able to swallow oral medications. 6. no continuous daily opioid as defined as more than 15 days in the 30 days before surgery. 7. undergoing tkr surgery. 8. patients who are willing and able to comply with scheduled visits and study procedures. exclusion criteria: 1. diagnosed with opioid use disorder (oud). 2. actively using illicit drugs. 3. allergy to opioids 4. older than 85 years

Keywords: pain
reduction nymphoplasty: assessment of the impact on sexuality, self-esteem and screening for dysmorphophobia

Conditions: Plastic Surgery

Summary: reduction nymphoplasty is the treatment of benign hyperplasia of the labia minora. this surgery is indicated in the event of functional, aesthetic or sexual discomfort. there has been a growing demand for this surgery over the past twenty years. it is necessary to remain vigilant because a request for cosmetic surgery can also be part of an obsession with body dysmorphism, former dysmorphophobia. investigators wish to study the postoperative results concerning sexuality, self-esteem and obsession with body dysmorphia in a cohort of patients followed prospectively and at more than 3 years postoperatively.


Eligibility criteria:
inclusion criteria: patients informed of the objectives of the study and its progress, exclusion criteria: patients in a period of exclusion determined by another study. patients under judicial safeguard, guardianship or curatorship. patients for whom it is impossible to give informed information.
the management of rt-induced hyposalivation using lllt

Conditions: Head and Neck Cancer

Summary: the primary purpose is to evaluate the effectiveness of photobiomodulation laser application in the management of patients with radiotherapy-induced hyposalivation. secondary, to assess the changes in the scores of the patient's oral health-related quality of life using validated measurements.

head and neck cancer is a general term used to describe epithelial malignancies in the oral cavity, paranasal sinuses, nasal cavity, pharynx, and larynx. these malignancies are often presented as squamous cell carcinoma (scc) of the head and neck with tobacco and alcohol consumption remaining the two main risk factors. in addition, human papillomavirus has been identified as another risk factor in a limited subset of these malignancies. more specifically, oral cancer accounts for 2%-4% of all cancer worldwide with 90% of these cases presented as ssc worldwide compared to 44.8% in saudi arabia. clinically, patients often presented with white and/or red patches, hoarseness, non-healed ulcers, throat pain, and painless cervical lump which may persist for more than 3 weeks period. most head \& neck cancer patients who received radiotherapy are likely to experience xerostomia and salivary glands hypofunction, mucositis, and possibly the loss of taste. furthermore, the effect of hyposalivation is not only limited to taste dysfunction but also associated with opportunistic infections, difficulty in chewing and speaking, rapid progression of caries, and oral mucositis. all these secondary complications are usually associated with pain and discomfort which will heavily affect the patient quality of life if they are untreated. treatment options include moisturizing agents or artificial saliva which have a palliative effect however they are not preferred nor accepted by most patients. the outcome of low-level laser therapy usage on cancer patients is well documented and well established in the literature. the vast majority of the results suggest that this therapy is an effective treatment option to stimulate salivary glands flow and decrease xerostomia/hyposalivation symptoms. in the present study, the efficiency of this treatment option will be tested as well as the changes in the patient's quality of life during and after the radiation treatment.

Eligibility criteria:
inclusion criteria: * patients aged 18 and above * clinically diagnosed with hyposalivation \[an unstimulated salivary flow rate of ≤ 0.1ml per minute\] (31) due to recent radiation therapy of scc of the head and neck. exclusion criteria: * individuals with systemic diseases that could affect the salivary glands function such as (e.g. sjogren syndrome) and medications (e.g. beta-blockers and diuretics for hypertension). * individuals who had an allergy to toluidine blue stain.
a study of the smart stent in the treatment sfa disease.

Conditions: Peripheral Artery Disease

Summary: the main objective of this study is to assess the safety and performance of the sirolimus coated cordis smart™ nitinol self expandable stent device and its delivery system in the treatment of obstructive superficial femoral artery (sfa) disease in reducing percent in-stent mean lumen diameter stenosis in de novo or restenotic native lesions as compared to the uncoated smart™ stent.

this is a multi-center, prospective, randomized, double blind, two-arm feasibility study evaluating the safety and performance of the sirolimus coated cordis smart™ nitinol self-expanding stent and delivery system as compared to the uncoated smart™ stent and delivery system. it is anticipated that a total of 90 patients will be entered into the study. patients will be randomized on a 1:1 basis of coated to uncoated stents. ninety (90) patients with de novo or restenotic native sfa lesions will be randomized to the sirolimus coated smart™ nitinol self-expanding stent or to the uncoated (bare) smart™ stent. patients will be followed for 24 months post-procedure, with all patients having duplex ultrasound and clinical assessments at discharge, 1, 6, 9, 18 and 24 months, angiography at 6 six months and plain x-ray at 18 months. this study will be conducted at nine investigational sites. (protocol was amended where 56 additional patients were recruited and followed for up to 5 years.)

Eligibility criteria:
inclusion criteria: 1. one superficial femoral artery presenting \> 70% stenosis(es) or total occlusion 2. symptomatic leg ischemia by rutherford classification (category 1, 2, 3 or 4) exclusion criteria: 1. tissue loss due to ischemic disease (rutherford category 5 or 6). 2. tandem lesion requiring non overlapping stents;
a safety extension study of dr-oxy-301

Conditions: Overactive Bladder

Summary: this is a safety extension study of dr-oxy-301 at pre-selected sites. subjects who complete the dr-oxy-301 study are eligible to participate. the duration of this extension study will be up to approximately 42 weeks. subjects will have physical and laboratory exams, including blood draws at each scheduled visit and colposcopic examination of the vagina and cervix. as in dr-oxy-301, subjects will be required to insert a vaginal ring; replacing it every 4 weeks. subjects will also be required to keep a daily record of the number of times and the total amount of time the ring was outside the body each day and the reason for voluntary removal.


Eligibility criteria:
inclusion criteria: * completed the 12 weeks of treatment in the dr-oxy-301 study * willing to limit medications for overactive bladder to investigational product only * able to understand and complete all study procedures including the required diary
numitor study: nummular headache iberian study on the treatments and outcomes in real-world setting

Conditions: Headache Disorders, Secondary; Headache Disorders; Central Nervous System Diseases; Brain Diseases; Neurologic Manifestations; Nervous System Diseases; Pain

Summary: the numitor study is an analytical observational study with an multicenter ambisective (retrospective and prospective) cohort design.

this study aims to create a multicenter registry that will increase the knowledge of nummular headache and assess which treatments are more effective and better tolerated. the study population will be patients with nummular headache who, under the opinion of their responsible neurologists, have required or require preventive treatment, in any of its modalities, oral or injectable.

Eligibility criteria:
inclusion criteria: 1. nummular headache according to the criteria of the international classification of headache disorders, third version (ichd-3). 2. nummular headache duration of more than three months. 3. treatment with a medication with possible preventive drug according to the clinical practice guidelines of the spanish society of neurology21. 4. age over 18 years. 5. informed consent signature. exclusion criteria: 1. diagnosis is better accounted for by any other entity included in the international classification of headache disorders, 3rd version. 2. serious systemic or psychiatric pathology that makes it difficult to assess the patient. 3. secondary nummular headache 4. use of preventive treatment with another indication (e.g., epilepsy, other painful conditions, aesthetic).
effects of treadmill versus cycling endurance training in patients with copd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: aim of this study is to investigate the effects of treadmill versus cycling endurance training on balance, gait performance and exercise capacity in patients with severe chronic obstructive pulmonary disease. patients will be recruited during a 3-week inpatient pulmonary rehabilitation program and will be randomized into one of two intervention groups. walking intensity in the treadmill group will be set at 80 percent of the average speed of the 6-minute walking test. the cycling group will exercise at an intensity of 60 percent according to an initial incremental cycling test. patients will perform 5 to 6 training sessions per week. the total exercise duration will be progressively increased from 10 to 30 minutes. walking or cycling intensity will also be progressively increased if perceived exertion during exercise is rated below 3 on the modified 10-point borg scale.


Eligibility criteria:
inclusion criteria: * copd stage iii or iv according to the global initiative for chronic obstructive lung disease * impaired exercise capacity (6 minute walk distance of less than 70% of the reference values from troosters et al.) exclusion criteria: * acute, severe exacerbation of copd * carbon dioxide of more than 45 mmhg at rest * any disabilities that prevent patient form walking or cycling * patient is not able to walk 20 meters without any aid (for example rollator)

Keywords: copd exercise training cycling treadmill walking pulmonary rehabilitation
establishing walking-related digital biomarkers in rare childhood onset progressive neuromuscular disorders

Conditions: Spinal Muscular Atrophy Type 3; Duchenne Muscular Dystrophy (DMD)

Summary: the purpose of this research is (1) to identify disease specific walking-related digital biomarkers of disease severity, and (2) monitor longitudinal changes in natural environments, for extended periods of time, in dmd and sma.

spinal muscular atrophy (sma) and duchenne muscular dystrophy (dmd) are genetic disorders that often result in progressive weakness and impaired function. our recent findings suggest that novel machine-learning (ml)-based abstraction models may map noisy signals from foot-worn sensors (namely, instrumented insoles developed by the project team) into accurate and clinically relevant spatiotemporal and kinetic gait parameters. these gait parameters derived from instrumented insoles may serve as functional biomarkers to detect changes in real world function. all participants will be observed and measured while wearing the instrumented insoles in the lab and in real-life environments.

Eligibility criteria:
inclusion criteria: one of the following categories: genetic confirmation of disease (dmd, sma) or healthy control able to walk independently at least 25 meters cohort specific inclusion criteria include: ongoing corticosteroids therapy or initiation of corticosteroid therapy in the previous 3 months for dmd stable dose of fda approved smn up-regulator therapy or in an open-label extension phase of a study treatment for at least 6 months for sma or gene replacement at enrollment for sma or dmd participants. exclusion criteria use foot orthoses or assistive devices for community ambulation or a mobility device for community navigation, use investigational medications intended for treatment of nmd within 30 days prior to study entry had an injury or surgery that would impact gait within the previous 3 months

Keywords: sma spinal muscular atrophy duchenne muscular dystrophy dmd instrumented insole neuromuscular disease machine learning model gait analysis functional biomarker wearable six minute walk test ambulatory becker phenotype
supportive oncology care at home for patients with pancreatic cancer receiving preoperative folfirinox

Conditions: Pancreas Cancer

Summary: the goal of this research is to study an intervention, which the investigators call "supportive oncology care at home," that entails both remote patient monitoring (e.g. patient-reported symptoms, home monitored vital signs, and body weight) and a medically home care model (e.g. triggers for phone calls and visits to patients' homes to address and manage any concerning issues identified). specifically, the investigators will conduct a single arm pilot study (n=20) in patients with pancreatic cancer who sign consent for parent trial of neoadjuvant folfirinox (18-179) receiving preoperative folfirinox to assess the feasibility and acceptability of supportive oncology care at home.

preoperative treatment can cause significant morbidity and often result in hospitalizations. patients receiving preoperative folfirinox often experience numerous side effects, including nausea, vomiting, diarrhea, fatigue, fever, neuropathy, and loss of appetite. frequently, patients require hospital admissions to help address uncontrolled symptoms related to their cancer and side effects related to the treatment, interventions targeting patients' symptoms and delivering care to patients at their homes have the potential to improve patient outcomes. studies show that interventions targeting patients' symptoms can improve symptom management, enhance quality of life (qol), and prevent hospitalizations. medically home interventions have shown the potential to enhance patient outcomes. the medically home model of care is an alternative to a hospital admission for acute care and treatment of a clinical condition. medically home interventions entail providing medical care to acutely ill patients in their home. in addition, research in the general medicine literature has demonstrated that interventions involving remote patient monitoring with 'triggers' for visits to patients' homes for worrisome symptoms can enhance care outcomes. although this research demonstrates promising results, these studies have not been conducted among patients with cancer. notably, the prior work involving home monitoring with visits as needed has lacked patient-reported outcomes, such as symptom monitoring. thus, efforts are needed to develop and test interventions containing both symptom monitoring and the potential for home visits when necessary in a population of patients with cancer.

Eligibility criteria:
inclusion criteria: * age 18 or older * within three weeks of signing consent for parent trial of neoadjuvant folfirinox * planning to receive care at massachusetts general hospital * ability to read and respond to questions in english * residing within 50 miles of massachusetts general hospital exclusion criteria: -uncontrolled psychiatric illness or impaired cognition

Keywords: pancreas cancer
swallowing evaluation in vf immobility

Conditions: Swallowing Disorder

Summary: vocal fold immobility (vfi) often results in significant problems with dysphonia, dysphagia, and decreased cough strength. as one element of the dysphagia potentially associated with vocal fold immobility, aspiration may create significant morbidity for these patients. an estimated 38% to 53% of patients with untreated vfi have swallowing difficulties with aspiration. vocal fold immobility has important implication on the laryngeal airway protection during respiration, phonation and swallowing. it is the most common neurological laryngeal disorder. the immobility may be caused by neck and thoracic surgery. which can impair the innervation of the pharynx, upper esophageal sphincter (u.e.s) and proximal esophagus but may also be due to malignancy,trauma, intracranial causes,or may be idiopathic

besides the voice alteration, the lesion that causes of vocal fold immobility should also affect the pharyngeal phase of swallowing. it was suggested that dysphagia in patient with vocal fold immobility has multifactor causes ; including limited airway protection and decrease laryngopharyngeal sensation based on the finding of the flexible endoscopy. another study revealed that pharyngeal phase abnormalities such as delayed initiation of swallowing, reduced laryngeal elevation, and reduced upper esophageal sphincter (ues) opening were found in video fluoroscopic swallowing studies (vfss). several studies on the swallowing difficulties of patient with vocal fold immobility has been performed and reported that nearly 56% of these patients immobility have swallowing dysfunction.

Eligibility criteria:
inclusion criteria: 1. age:above 18. 2. gender:both sexes will be included in the study. exclusion criteria: 1. patients with structural abnormalities of oral cavity, pharynx or larynx. 2. previous vocal fold injection or voice therapy. 3. other causes of dysphagia: esophageal cancer or spasm , gastric cancer, cancer larynx,or radio therapy . 4. . patients with history of heart burn , acid regurgitation , 5. other neurological disease ,stroke, hypothyroidism or dyspnea.
covid-19 immunity and changes over time

Conditions: COVID-19

Summary: the risk of household spread of sars-cov-2 hinges on both the transmission dynamics of the virus circulating in the community as well as the seroprotection pattern of constituent members, which can be attributed to vaccination and previous infections. this study is conceptualised to assess the dynamicity of sars-cov-2 risk at the household level, through monitoring the pattern of seroprotection, in conjunction with the vaccination coverage, history of infection and exposure risk in the setting of hong kong.

the aim of this study is to assess the sars-cov-2 risk at the household level, with the objectives of (a) determining the coverage of vaccination and its changes over time; (b) monitoring pattern of exposure and history of infection; and (c) evaluating the level of seroprotection and its longitudinal trend. a cohort of households comprising 900 persons would be recruited. invited participants would be attend the research centre for blood sampling and the completion of a simple questionnaire at 3 different timepoints at 12-18 months apart. a questionnaire would be administered to capture the following characteristics: (a) socio-demographics; (b) history of sars-cov-2 infection; (c) adoption of precautionary measures; (d) sars-cov-2 testing history and (e) sars-cov-2 vaccination uptake. participants would be tested for sars-cov-2 serology. the main markers for measurement are nucleocapsid antibody for inferring past infection, spike antibody for the immunological responses, and seroprotection by sars-cov-2 surrogate virus neutralisation test.

Eligibility criteria:
inclusion criteria: * adults of age 18 or above, or children under the age of 18 with informed consent of the legal guardian * normally residing in hong kong * could communicate in spoken and written chinese and/or english exclusion criteria: * individuals with mental illness * prisoners

Keywords: serology cohort study sars-cov-2 antibody